- 米国企業
- NEKTAR THERAPEUTICS
NEKTAR THERAPEUTICSNKTR
時価総額
$3.3億
PER
2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | |
Cash and cash equivalents | 15 | 25 | 39 | 12 | 56 | 60 | 5 | 195 | 96 | 199 | 25 | 88 |
Short-term investments | - | - | - | - | - | - | - | 1,140 | 1,228 | 863 | 709 | 417 |
Accounts receivable | 5 | 6 | 2 | 4 | 20 | 16 | 5 | 43 | 37 | 39 | 22 | 6 |
Inventory | 13 | 18 | 13 | 13 | 11 | 11 | 11 | 11 | 13 | 15 | 16 | 19 |
Other current assets | 18 | 13 | 5 | 9 | 10 | 10 | 15 | 21 | 15 | 18 | 23 | 16 |
Total current assets | 277 | 315 | 258 | 288 | 350 | 426 | 327 | 1,438 | 1,422 | 1,138 | 796 | 546 |
Long-term investments | - | - | - | - | - | - | - | 583 | 279 | 137 | 65 | - |
Property, plant and equipment, net | 79 | 72 | 67 | 70 | 71 | 66 | 47 | 49 | 65 | 60 | 61 | 32 |
Operating lease right-of-use assets | - | - | - | - | - | - | - | - | 134 | 126 | 117 | 53 |
Goodwill | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 | 77 |
Other assets | 1 | 9 | 8 | 7 | 4 | 1 | 1 | 4 | 1 | 1 | 3 | 2 |
Total assets | 607 | 498 | 435 | 442 | 502 | 569 | 509 | 2,150 | 1,977 | 1,539 | 1,117 | 711 |
Accounts payable | 3 | 3 | 9 | 3 | 2 | 3 | 5 | 6 | 19 | 22 | 10 | 13 |
Accrued compensation | 13 | 9 | 14 | 6 | 6 | 18 | 8 | 10 | 11 | 15 | 16 | 10 |
Accrued clinical trial expenses | - | - | - | - | - | - | - | 15 | 33 | 44 | 27 | 12 |
Other accrued expenses | - | - | - | - | 4 | 5 | 10 | 9 | 11 | 10 | 15 | 15 |
Operating Lease, Liability, Current | - | - | - | - | - | - | - | - | 13 | 14 | 17 | 19 |
Total current liabilities | 276 | 79 | 98 | 64 | 61 | 72 | 56 | 82 | 354 | 116 | 85 | 68 |
Operating Lease, Liability, Noncurrent | - | - | - | - | - | - | - | - | 143 | 136 | 126 | 113 |
Development derivative liability | - | - | - | - | - | - | - | - | - | - | 28 | - |
Liabilities related to the sales of future royalties, net | - | - | - | - | - | 106 | 95 | 83 | 72 | 200 | 195 | 155 |
Other long-term liabilities | 7 | 8 | 19 | 15 | 10 | 5 | 6 | 10 | 1 | 7 | 4 | 8 |
Total liabilities | 409 | 451 | 524 | 405 | 496 | 481 | 421 | 433 | 572 | 461 | 438 | 344 |
Preferred Stock, Value, Issued | - | - | - | - | - | - | - | - | - | - | - | - |
Common Stock, Value, Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital in excess of par value | 1,597 | 1,618 | 1,644 | 1,824 | 1,876 | 2,111 | 2,208 | 3,148 | 3,271 | 3,389 | 3,517 | 3,575 |
Accumulated other comprehensive loss | -1 | -0 | -1 | -2 | -2 | -2 | -2 | -6 | -1 | -2 | -4 | -7 |
Accumulated deficit | -1,399 | -1,570 | -1,732 | -1,786 | -1,867 | -2,021 | -2,118 | -1,424 | -1,865 | -2,309 | -2,833 | -3,201 |
Total stockholders’ equity | 198 | 47 | -90 | 36 | 6 | 88 | 88 | 1,718 | 1,405 | 1,077 | 680 | 367 |
Total liabilities and stockholders’ equity | 607 | 498 | 435 | 442 | 502 | 569 | 509 | 2,150 | 1,977 | 1,539 | 1,117 | 711 |